Kulkarni, Tejaswini
Criner, Gerard J.
Kass, Daniel J.
Rosas, Ivan O.
Scholand, Mary Beth
Dilling, Daniel F.
Summer, Ross
Duncan, Steven R.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (# U01HL133232, # U01HL133232, # U01HL133232, # U01HL133232, # U01HL133232, # U01HL133232, # U01HL133232, # U01HL133232)
Article History
Received: 16 February 2024
Accepted: 8 March 2024
First Online: 20 March 2024
Declarations
:
: The protocol was reviewed and approved by an independent DSMB. All participating sites obtained local Institutional Review Board (IRB) or WCG approvals. The approval numbers are:The University of Alabama: 170530011 (site), 170530010 (coordinating center),Temple University Hospital: WCG (UAB OSP#: 000513913).University of Pittsburgh Medical Center: CR19090031-010.Baylor University Medical Center: H-46682.University of Utah Medical Center: 0012631.Thomas Jefferson Medical Center: 20F307.Loyola University Medical Center: 212720112019.All participants will sign an informed consent to participate in the clinical trial.
: Not applicable.
: TK reports personal fees from Boehringer Ingelheim Inc, Puretech Inc, Veracyte, United Therapeutics, outside of submitted work. DJK reports consulting fees from Callidatas, outside of submitted work. DFD reports personal fees from Boehringer Ingelheim Inc, outside of the submitted work. RS reports personal fees from Iliad Biosciences, outside of the submitted work. MBS reports personal fees from Genentech, Boehringer Ingelheim, Veracyte, United Therapeutics, outside of the submitted work. GJK, IOR and SRD do not have competing interests.